Investors sold shares of Juno Therapeutics Inc (NASDAQ:JUNO) on strength during trading on Friday. $23.76 million flowed into the stock on the tick-up and $36.57 million flowed out of the stock on the tick-down, for a money net flow of $12.81 million out of the stock. Of all equities tracked, Juno Therapeutics had the 0th highest net out-flow for the day. Juno Therapeutics traded up $0.41 for the day and closed at $29.21

JUNO has been the topic of several research analyst reports. Leerink Swann restated a “buy” rating on shares of Juno Therapeutics in a research report on Thursday. Zacks Investment Research cut shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. FBR & Co restated a “buy” rating on shares of Juno Therapeutics in a research report on Saturday, July 9th. Maxim Group restated a “buy” rating and issued a $80.00 price objective on shares of Juno Therapeutics in a research report on Sunday, July 10th. Finally, Cowen and Company restated a “buy” rating and issued a $55.00 price objective on shares of Juno Therapeutics in a research report on Sunday, July 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $53.11.

The stock’s market cap is $2.96 billion. The stock has a 50-day moving average of $40.01 and a 200 day moving average of $38.03.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.26. The business earned $9.80 million during the quarter, compared to analysts’ expectations of $4.83 million. During the same period in the previous year, the company posted ($0.30) earnings per share. On average, equities analysts forecast that Juno Therapeutics Inc will post ($2.28) EPS for the current fiscal year.

In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 90,750 shares of the company’s stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $46.42, for a total transaction of $4,212,615.00. Following the completion of the sale, the chief executive officer now directly owns 2,704,609 shares of the company’s stock, valued at approximately $125,547,949.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Bernard J. Cassidy sold 3,116 shares of the company’s stock in a transaction that occurred on Thursday, May 19th. The shares were sold at an average price of $39.03, for a total value of $121,617.48. Following the sale, the general counsel now directly owns 55,511 shares of the company’s stock, valued at $2,166,594.33. The disclosure for this sale can be found here.

A number of hedge funds recently bought and sold shares of the stock. BBR Partners LLC bought a new stake in Juno Therapeutics during the fourth quarter valued at approximately $1,539,000. BNP Paribas Arbitrage SA increased its stake in Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 10,884 shares in the last quarter. Stevens Capital Management LP bought a new stake in Juno Therapeutics during the fourth quarter valued at approximately $2,315,000. Swiss National Bank bought a new stake in Juno Therapeutics during the fourth quarter valued at approximately $2,603,000. Finally, ProShare Advisors LLC bought a new stake in Juno Therapeutics during the fourth quarter valued at approximately $3,674,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.